Abstract
Biological staging of individuals with Alzheimer’s disease (AD) may improve diagnostic and prognostic work-up of dementia in clinical practice and the design of clinical trials. Here, we created a staging model using the Subtype and Stage Inference (SuStaIn) algorithm by evaluating cerebrospinal fluid (CSF) amyloid-β (Aβ) and tau biomarkers in 426 participants from BioFINDER-2, that represent the entire spectrum of AD. The model composition and main analyses were replicated in 222 participants from the Knight ADRC cohort. SuStaIn revealed in the two cohorts that the data was best explained by a single biomarker sequence (one subtype), and that five CSF biomarkers (ordered: Aβ42/40, tau phosphorylation occupancies at the residues 217 and 205 [pT217/T217 and pT205/T205], microtubule-binding region of tau containing the residue 243 [MTBR-tau243], and total tau) were sufficient to create an accurate disease staging model. Increasing CSF stages (0-5) were associated with increased abnormality in other AD-related biomarkers, such as Aβ- and tau-PET, and aligned with different phases of longitudinal biomarker changes consistent with current models of AD progression. Higher CSF stages at baseline were associated with higher hazard ratio of clinical decline. Our findings indicate that a common pathophysiologic molecular pathway develops across all AD patients, and that a single CSF collection is sufficient to reliably indicate the presence of both AD pathologies and the degree and stage of disease progression.
Competing Interest Statement
OH has acquired research support (for the institution) from ADx, AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, Fujirebio, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from AC Immune, Amylyx, Alzpath, BioArctic, Biogen, Cerveau, Eisai, Eli Lilly, Fujirebio, Genentech, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Siemens. JWV is supported by the SciLifeLab & Wallenberg Data Driven Life Science Program (grant: KAW 2020.0239). KH is an Eisai-sponsored voluntary research associate professor at Washington University and has received salary from Eisai. Washington University, RJB, and DMH have equity ownership interest in C2N Diagnostics. RJB. and DMH receive income from C2N Diagnostics for serving on the scientific advisory board. KH, NRB, and RJB. may receive income based on technology (METHODS TO DETECT MTBR TAU ISOFORMS AND USE THEREOF) licensed by Washington University to C2N Diagnostics. DMH may receive income based on technology (ANTIBODIES TO MID-DOMAIN OF TAU) licensed by Washington University to C2N Diagnostics. RJB has received honoraria as a speaker, consultant, or advisory board member from Amgen and Roche. DMH is on the scientific advisory board of Genentech, Denali, and Cajal Neurosciences, and consults for Alector and Asteroid. NRB is co-inventor on the following US patent applications: 'Methods to detect novel tau species in CSF and use thereof to track tau neuropathology in Alzheimer's disease and other tauopathies' (PCT/US2020/046224); 'CSF phosphorylated tau and amyloid beta profiles as biomarkers of tauopathies' (PCT/US2022/022906); and 'Methods of diagnosing and treating based on site-specific tau phosphorylation' (PCT/US2019/030725). NRB may receive a royalty income based on technology licensed by Washington University to C2N Diagnostics.
Funding Statement
The BioFINDER study was supported by the Swedish Research Council (2022-00775), ERA PerMed (ERAPERMED2021-184), the Knut and Alice Wallenberg foundation (2017-0383), the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University, the Swedish Alzheimer Foundation (AF-980907), the Swedish Brain Foundation (FO2021-0293), The Parkinson foundation of Sweden (1412/22), the Cure Alzheimer's fund, the Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, the Skane University Hospital Foundation (2020-O000028), Regionalt Forskningsstod (2022-1259) and the Swedish federal government under the ALF agreement (2022-Projekt0080). The precursor of 18F-flutemetamol was sponsored by GE Healthcare. The precursor of 18F-RO948 was provided by Roche. GS received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie action grant agreement No 101061836, from an Alzheimer's Association Research Fellowship (#AARF-22-972612), Greta och Johan Kocks research grants and, travel grants from the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson's disease) at Lund University. This work was supported by resources and effort provided by the Tracy Family SILQ Center (PI: RJB) established by the Tracy Family, Richard Frimel and Gary Werths, GHR Foundation, David Payne, and the Willman Family brought together by The Foundation for Barnes-Jewish Hospital. This work was also supported by resources and effort provided by the Hope Center for Neurological Disorders and the Department of Neurology at the Washington University School of Medicine. This work was also supported by the Clinical, Fluid Biomarker, and Imaging Cores of the Knight ADRC (P30 AG066444 [PI: JCM], P01 AG03991 [PI: JCM], and P01 AG026276 [PI: JCM]) at the Washington University School of Medicine for participant evaluation, samples, and data collection. The mass spectrometry analyses of BioFINDER-2 and Knight ADRC samples were supported by Eisai industry grant to Washington University (PI: KH and RJB) and the Knight ADRC developmental project (PI: NRB) and R01AG070941 (PI: SES). The funding sources had no role in the design and conduct of the study; in the collection, analysis, interpretation of the data; or in the preparation, review, or approval of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent and ethical approval was granted by the Regional Ethical Committee in Lund, Sweden and the Washington University Human Research Protection Office, respectively.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
